Related Experiment Video
Updated: May 19, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Domperidone: ventricular arrhythmia and sudden death (continued)
Abstract:
Domperidone, a "hidden" neuroleptic, is used for symptomatic treatment of gastroesophageal reflux disease, despite its uncertain efficacy. The intravenous form was withdrawn from the market in the 1980s following deaths due to cardiac arrhythmias. QT prolongation leading to cardiac arrhythmias, including life-threatening torsades de pointes, has also been attributed to oral domperidone. In 2010, two case-control studies, one Canadian and one Dutch, showed that patients who died suddenly or had severe ventricular arrhythmias were statistically significantly more likely than controls to have been exposed to domperidone. In practice, given its uncertain efficacy and a disproportionate risk of sudden death and severe ventricular arrhythmia, domperidone should not be used.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Dysrhythmias IV: Characteristics of Bradyarrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Dysrhythmias VI: Management of Dysrhythmias

